Strategy

We strive to significantly improve the lives of cancer patients by developing revolutionary products which specifically target tumors. Our aim is to provide more focused therapies which have a higher efficacy and fewer side effects than those that are currently available.

Creating value:

• pipeline of drug candidates
• product and technology platform based on a tumor-specific marker

Commercialization:

• outlicensing of drug candidates to pharma and internationally active biotechnology companies, typically on the basis of phase I/II data
• selected co-development partnerships for complementary technologies